Your email has been successfully added to our mailing list.

×
0 0 0 0 0 -1.57478443209242E-16 -1.57478443209242E-16 -1.57478443209242E-16
Stock impact report

Akcea Completes Enrollment in Phase 2b Study of AKCEA-APO(a)-LRx

AKCEA THERAPEUTICS (AKCA) 
Last akcea therapeutics earnings: 2/25 04:05 pm Check Earnings Report
Company Research Source: GlobeNewswire
CAMBRIDGE, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), today announced it had completed enrollment of a Phase 2b clinical study of investigational drug AKCEA-APO(a)-LRx. Akcea is conducting the study in patients with high Lp(a) and established cardiovascular disease (CVD) to determine the dose level and frequency of administration for a future planned Phase 3 cardiovascular outcome study and to determine the safety and tolerability profile of AKCEA-APO(a)-LRx. Akcea plans to report top-line data from the Phase 2b study in the second half of 2018. Akcea is an affiliate of Ionis Pharmaceuticals Inc. focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders.  AKCEA-APO(a)-LRx is part of a strategic collaboration with Novartis. If Novartis exercises its option to license AKCEA-APO(a)-LRx after successful completion of the Phase 2b study, it will be responsible for all future dev Show less Read more
Impact Snapshot
Event Time:
AKCA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for AKCA alerts
Opt-in for
AKCA alerts

from News Quantified
Opt-in for
AKCA alerts

from News Quantified